Diseases of the Cardiovascular System | Diseases of the Nervous System, Phase III
Anticoagulation for Stroke Prevention and Recovery After ICH (ASPIRE)
Volunteers
Health Professionals
What is the purpose of this trial?
Brief Summary:
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF).
Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
- Trial withUniversity of Cincinnati
- Ages18 years and older
- GenderBoth
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Adam de Havenon, MD, MSCI
- Adam Jasne, MD
- Caitlin Loomis, MD
- Emily J. Gilmore, MD, FNCS, FACNS
- James A. Giles, MD, PhD, MPHS, MRCP
- Jennifer Ahjin Kim, MD/PhD
- Jessica Magid-Bernstein, MD, PhD
- Jorge Rodriguez
- Joseph Schindler, MD
- Kevin Sheth, MD
- Lauren Hachmann Sansing, MD, MS, FAHA, FANA
- Mark Warman, MD, MSc, MA
- Morgan Lippitt Prust, MD
- N. Abimbola Sunmonu, MD/PhD
- Nils Petersen, MD/PhD, MSc
- Nishant Kumar Mishra, MD, PhD, FRCP, FAHA
- Rachel Beekman, MD
- Rachel Forman, MD
- Reshma Narula, MD
- Richa Sharma, MD, MPH
- Ruth Arnold
- Stefanie Cappucci, MD
- Syed Ali
- Last Updated11/01/2024
- Study HIC#2000026409